威高股份：中期報告2025.pdf

1、1 1概要山東威高集團醫用高分子製品股份有限公司（本公司）及其附屬公司（本集團）截至二零二五年六月三十日止六個月（期間），未經審核之收入約人民幣6,644,048,000元（二零二四年同期：約人民幣6,635,688,000元），較去年同期增長約0.1%，未經審核之本公司擁有人應佔純利約人民幣1,008,317,000元（二零二四年同期：約人民幣1,107,549,000元），較去年同期下跌約9.0%。不計特殊項目的本公司擁有人應佔純利約人民幣967,095,000元，較去年同期可比數（二零二四年同期：約人民幣1,107,549,000元）下跌約12.7%。董事會（董事會）建議派發截至二零二五

2、年六月三十日止六個月之中期股息每股人民幣0.0969元（二零二四年同期：每股人民幣0.0919元）。該建議須經本公司股東（股東）在即將舉行的股東特別大會上批准後，方可作實。SUMMARYFor the six months ended 30 June 2025(the“Period”),the unaudited revenue of Shandong Weigao Group Medical Polymer Company Limited(the“Company”)and its subsidiaries(the“Group”)was approximately RMB6,644,048,0

3、00(same period in 2024:approximately RMB6,635,688,000),representing an increase of approximately 0.1%as compared with the same period last year,the unaudited net profit attributable to the owners of the Company was approximately RMB1,008,317,000(same period in 2024:approximately RMB1,107,549,000),re

4、presenting a decrease of approximately 9.0%as compared with the same period last year.Net profit attributable to the owners of the Company(excluding extraordinary items)was approximately RMB967,095,000,representing a decrease of approximately 12.7%as compared to comparable figure(same period in 2024

5、:approximately RMB1,107,549,000)over the same period last year.The board of directors(the“Board”)proposed the distribution of an interim dividend for the six months ended 30 June 2025 of RMB0.0969 per share(same period in 2024:RMB0.0919 per share).The proposal is subject to the approval of sharehold

6、ers of the Company(the“Shareholders”)at the forthcoming extraordinary general meeting.SHANDONG WEIGAO GROUP MEDICAL POLYMER COMPANY LIMITEDINTERIM REPORT 2025山東威高集團醫用高分子製品股份有限公司2025 中期報告 2未經審核簡明綜合中期業績 董事會欣然宣佈本集團於截至二零二五年六月三十日止六個月未經審核簡明綜合中期業績，連同二零二四年同期*未經審核比較數字如下：未經審核簡明綜合全面收益表*上期的比較數字已作重新呈列，以按職能屬性重新分類